Sten Randahl Sörensen
Chief Executive Officer at CERENO SCIENTIFIC AB
Profile
Sten Randahl Sörensen is currently the Chief Executive Officer at Cereno Scientific AB since 2015.
He is also the Executive Chairman at SARomics Biostructures AB since 2013 and the Director at SynAct Pharma AB since 2024.
Previously, he served as the Chairman at AcuCort AB and Stayble Therapeutics AB.
He was also the Director of Secondary Prevention Products Marketing at AstraZeneca AB.
From 1987 to 1995, he held the position of Head of International Marketing Operations at Monsanto Crop Sciences Sweden AB.
Mr. Sörensen completed his undergraduate degree at the University of Lund.
Sten Randahl Sörensen active positions
Companies | Position | Start |
---|---|---|
CERENO SCIENTIFIC AB | Chief Executive Officer | 2015-08-31 |
SYNACT PHARMA AB | Director/Board Member | 2024-03-19 |
SARomics Biostructures AB
SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Chairman | 2012-12-31 |
Former positions of Sten Randahl Sörensen
Companies | Position | End |
---|---|---|
Monsanto Crop Sciences Sweden AB | Sales & Marketing | 1994-12-31 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Sales & Marketing | - |
STAYBLE THERAPEUTICS AB | Chairman | - |
ACUCORT AB | Chairman | - |
Training of Sten Randahl Sörensen
University of Lund | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
ACUCORT AB | Health Technology |
SYNACT PHARMA AB | Health Technology |
CERENO SCIENTIFIC AB | Health Technology |
STAYBLE THERAPEUTICS AB | Health Technology |
Private companies | 3 |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Monsanto Crop Sciences Sweden AB | |
SARomics Biostructures AB
SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Health Technology |
- Stock Market
- Insiders
- Sten Randahl Sörensen